---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000052"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-05-29T23:59:59+00:00"
generated_at: "2026-05-20T05:53:14.731459+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Keros ends PAH program, cuts 45% of staff, expects $17M annual savings

## Summary
- TROPOS trial discontinued after pericardial effusion safety events; all cibotercept PAH development halted.
- Workforce reduced ~45% to 85 employees; one-time severance charges of ~$3.2M in Q2 2025.
- Annualized cost savings of ~$17M expected; restructuring substantially complete by Q4 2025.
- Strategic alternatives review ongoing; preliminary update to be provided by June 9, 2025.

## SEC filing metadata
- accession: 0001664710-25-000052
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-05-29T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000052/0001664710-25-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000052/kros-20250528.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000052
- JSON: https://secwatch.observer/filing/0001664710-25-000052.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000052.txt

## Key facts
- Restructurings & Charges
  Keros Therapeutics, Inc. announced a restructuring with charges of approximately $3.2 million (approximately 45%).
  - Type: restructuring
  - Charge: approximately $3.2 million
  - Headcount: approximately 45%
  source text: These plans were communicated to affected employees on May 29, 2025. The Company expects to incur one-time cash charges associated with the Reorganization of approximately $3.2 million related to employee severance payments and related costs, which are expected to be expensed in the second quarter of 2025. In addition, the Company has committed to pay one-time
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000052/0001664710-25-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.